Krishna K. Rathnam

Meenakshi Mission Hospital & Research Centre
Madurai, TN, IN 
Clinical Trials:Currently Recruiting for 1 Trial
Meenakshi Mission Hospital & Research Centre
Madurai, TN, IN 

Overview

Krishna Rathnam practices practicing medicine in Madurai, India.

Their clinical expertise encompasses Ovarian Cancer, Xeroderma Pigmentosum, Triple-Negative Breast Cancer, Breast Cancer, and Orchiectomy.

They are actively involved in clinical research, co-authoring 12 peer reviewed articles and participating in 2 clinical trials.

Locations

Meenakshi Mission Hospital & Research Centre
Madurai, TN 625107, India
Other Locations
BMCHRC
Jaipur, RJ, India

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
View 1 Less Clinical Trial

12 Total Publications

Emerging LncRNA HOTAIR and NME1 polymorphisms in ovarian cancer risk: A pilot case-control study in South Indian women.
Emerging LncRNA HOTAIR and NME1 polymorphisms in ovarian cancer risk: A pilot case-control study in South Indian women.
Journal: Clinica chimica acta; international journal of clinical chemistry
Published: January 15, 2026

Frequently Asked Questions about Krishna K. Rathnam

Is Krishna K. Rathnam a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Krishna K. Rathnam is classified as an Experienced expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Krishna K. Rathnam participate in research or clinical trials?

Yes. Krishna K. Rathnam has published 12 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Krishna K. Rathnam's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Rathnam's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile